ArticleFrontiers in pediatrics2026
Methylprednisolone sodium succinate combined with azithromycin in the treatment of Mycoplasma pneumonia in children and Its effect on immune function.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy of methylprednisolone sodium succinate combined with azithromycin in the treatment of pediatric bronchopneumonia, and to explore its comprehensive effects on immune regulation and inflammation relief. Methods: This retrospective controlled study included 120 pediatric patients with bronchopneumonia diagnosed in our hospital from October 2021 to March 2025. According to the treatment regimen, patients were divided into two groups: the experimental group ( Results: Compared with the control group, the overall efficacy of the experimental group was significantly better (total effective rate: 93.3% vs. 80.0%, Conclusion: Methylprednisolone sodium succinate combined with azithromycin can effectively shorten the course of mycoplasma bronchopneumonia in children, improve clinical symptoms, reduce inflammatory responses, and enhance immune responses. Under the premise of ensuring safety, it has advantages over azithromycin alone and has good clinical application prospects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.